The five studies highlighted that RASi exert their efficacy through two core mechanisms: (1) the inhibition of the pro-tumor ACE/AngII/AT1R axis and (2) the enhancement of the anti-tumor ACE2/Ang(1-7)/MasR axis. Here, AGTR1 is linked to neoplasm.